Status:
UNKNOWN
OCT and Microperimetry in Patients With Active Neovascular ARMD (CORFI)
Lead Sponsor:
University Hospital, Limoges
Conditions:
Choroidal Neovascularization, Visual Field, Visual Acuity
Eligibility:
All Genders
50+ years
Brief Summary
ARMD is the main cause of visual disability after 50 years old in France. Patients with active neovascular ARMD are treated with intravitreal injections of antiVEGF. Reinjections criteria are decrease...
Eligibility Criteria
Inclusion
- patients \> 50 years old,
- With neovascular ARMD
- who need an induction treatment (de novo patients or patients who had their last intravitreal injection of antiVEGF more than 6 months ago)
Exclusion
- Other maculopathies
- Severe glaucoma with central visual field defect
- Diabetic patients
- Corneal, lens or vitreous opacities interfering in OCT analysis
- Attention or comprehension deficit
Key Trial Info
Start Date :
February 13 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 13 2021
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03435926
Start Date
February 13 2018
End Date
February 13 2021
Last Update
January 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Limoges, France, 87042